Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QuANTUM-Wild in newly diagnosed FLT3-ITD-negative acute myeloid leukemia
jRCT2061240069Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of quizartinib in acute myeloid leukemia (AML) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Overall survival. Started Feb 2025; status: active, not recruiting.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2061240069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240069.